Benitec Biopharma (BNTC) Total Liabilities (2019 - 2025)

Benitec Biopharma has disclosed Total Liabilities across 7 years of filings, most recently posting $3.3 million for Q4 2025.

• Total Liabilities for Q4 2025 came in at $3.3 million, up 6.17% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.3 million (up 6.17% YoY), and the FY2025 annual result was $2.3 million, down 53.71% from the prior year.
• Total Liabilities came in at $3.3 million for Q4 2025 at Benitec Biopharma, up from $2.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $7.6 million in Q1 2025 to a low of $1.4 million in Q2 2021.
• The 5-year median for Total Liabilities is $3.2 million (2021), against an average of $3.6 million.
• Across the five-year window, Total Liabilities surged 258.29% in 2021 and slumped 53.71% in 2025, its largest moves.
• Benitec Biopharma's Total Liabilities stood at $3.2 million in 2021, then dropped by 8.4% to $2.9 million in 2022, then jumped by 102.1% to $5.9 million in 2023, then tumbled by 46.85% to $3.1 million in 2024, then grew by 6.17% to $3.3 million in 2025.
• The last three Total Liabilities figures came in at $3.3 million (Q4 2025), $2.4 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.